Please ensure Javascript is enabled for purposes of website accessibility
ホーム > 製品 > 抗体 > バイオシミラー

Anti-Ganglioside GD2 Reference Antibody (Naxitamab, RUO) (YP115036)

Anti-Ganglioside GD2 Reference Antibody (Naxitamab, RUO)
Anti-Ganglioside GD2 Reference Antibody (Naxitamab, RUO)
Anti-Ganglioside GD2 Reference Antibody (Naxitamab, RUO)
Anti-Ganglioside GD2 Reference Antibody (Naxitamab, RUO)
価格(USD):
スペック:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
数量:
お問い合わせ
  • 概要

  • イメージ

  • 参考文献

  • データシート

  • SDS

概要
カタログ番号YP115036
説明
Naxitamab (YP115036) is a research-grade recombinant antibody targeting Ganglioside GD2. Produced in mammalian cells with native-like glycosylation.
Highlights
  • ●Research Grade — For PK/PD studies, assay development, and ADA research.
  • ●Native Glycosylation — Mammalian expression ensures native-like patterns.
種反応性General
アプリケーションELISA, Bioactivity: FACS, Functional assay, Research in vivo
宿主種Chimeric
クローン性Monoclonal
アイソタイプIgG1, kappa
発現システム Mammalian cells
ターゲット Ganglioside GD2
エンドトキシンレベル < 10 EU/mg
純度 >95% purity as determined by SDS-PAGE.
精製 Protein A/G purified from cell culture supernatant.
形態 Liquid
保存バッファー 0.01M PBS pH 7.4

データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。

安定性と保存 Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
別名Hu3F8, Naxitamab-gqgk, CAS: 1879925-92-4
背景Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity.
• Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer., PMID:34596246
• GD2 is a Crucial Ganglioside in the Signal Modulation and Application as a Target of Cancer Therapeutics., PMID:39921214
• Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers., PMID:38593230
• Ganglioside GD2 Contributes to a Stem-Like Phenotype in Intrahepatic Cholangiocarcinoma., PMID:39726234
• Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma., PMID:33479234
• Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins., PMID:35008849
• RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype., PMID:32486168
• Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas., PMID:29662203
• Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma., PMID:20879881
注意事項 For research use only. Not suitable for clinical or therapeutic use.
イメージ
  • Anti-Ganglioside GD2 Reference Antibody (Naxitamab, RUO)

    Bioactivity

    SEC-HPLC detection for Research Grade Naxitamab.

  • Anti-Ganglioside GD2 Reference Antibody (Naxitamab, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Naxitamab.

参考文献
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
レコメンデーション

お問い合わせ カスタムクォート、大量リクエストおよびその他の問題については

メール: [email protected]

ディストリビューターリスト